South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.
With Johnson & Johnson's diabetes drug Invokana going up against two longtime rivals in China, the company is ramping things up.
The FDA issued a warning letter after an inspection of the China plant where Zhuhai United Laboratories makes sterile drugs.
Nasdaq-listed Sinovac accused OrbiMed, 1Globe Capital and a buyer consortium led by Sinobioway of conspiring a hostile takeover.
Zhejiang Huahai Pharmaceutical informed the EMA that it had identified a chemical that might lead to cancer in its valsartan provided to the European market.
A film based on the true story of a leukemia patient smuggling Indian generics has led Beijing to reiterate its intention to cut cancer drug prices.
Boehringer Ingelheim is expanding the $77 million contract biologics plant it opened last year in Shanghai.
Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.
After opening its new global headquarters in Tokyo, Takeda is seeking buyers for its old headquarters in Osaka to help fund its Shire takeover.
The FDA has issued a warning letter for a Sichuan Friendly Pharmaceutical plant at Neijiang, Sichuan.